Strategies to retard the progression of chronic kidney disease

Medical Clinics of North America

Volumn 89, Issue 3, 2005, Pages 489-509

  Zandi Nejad, Kambiz ^a,b   Brenner, Barry M ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LISINOPRIL; LOSARTAN; METOPROLOL; NONSTEROID ANTIINFLAMMATORY AGENT; PERINDOPRIL; RAMIPRIL; TRANDOLAPRIL; VALSARTAN;

ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIET RESTRICTION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HUMAN; HYPERKALEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN INTAKE; PROTEINURIA; QUALITY OF LIFE; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SMOKING CESSATION;

EID: 14744288908     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2004.11.001     Document Type: Review

References (116)

1. A.S. Levey, J. Coresh, and E. Balk National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification Ann Intern Med 139 2003 137 147
2. National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases. USRDS 2001 annual data report: atlas of end-stage renal disease in the United States. 2003. Available at: http://www.usrds.org.
3. H.S. Trivedi, M.M. Pang, and A. Campbell Slowing the progression of chronic renal failure: economic benefits and patients' perspectives Am J Kidney Dis 39 2002 721 729
4. B.M. Brenner Retarding the progression of renal disease Kidney Int 64 2003 370 378
5. B.M. Brenner, D.L. Garcia, and S. Anderson Glomeruli and blood pressure. Less of one, more the other? Am J Hypertens 1 1988 335 347
6. B.M. Brenner, and G.M. Chertow Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury Am J Kidney Dis 23 1994 171 175
7. R.G. Nelson Intrauterine determinants of diabetic kidney disease in disadvantaged populations Kidney Int 63 Suppl 83 2003 S13 S16
8. G. Keller, G. Zimmer, and G. Mall Nephron number in patients with primary hypertension N Engl J Med 348 2003 101 108
9. M. Hughson, A.B. Farris III, and R. Douglas-Denton Glomerular number and size in autopsy kidneys: the relationship to birth weight Kidney Int 63 2003 2113 2122
10. B.D. Myers, W.M. Deen, and B.M. Brenner Effects of norepinephrine and angiotensin II on the determinants of glomerular ultrafiltration and proximal tubule fluid reabsorption in the rat Circ Res 37 1975 101 110
11. R. Zatz, B.R. Dunn, and T.W. Meyer Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension J Clin Invest 77 1986 1925 1930
12. C.E. Mogensen Management of the diabetic patient with elevated blood pressure or renal disease. Early screening and treatment programs: albuminuria and blood pressure J.H. Laragh B.M. Brenner Hypertension: pathophysiology, diagnosis, and management 2nd edition 1996 Raven New York 2335 2365
13. E.J. Lewis, L.G. Hunsicker, and R.P. Bain The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group N Engl J Med 329 1993 1456 1462
14. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data Ann Intern Med 134 2001 370 379
15. E.R. Mathiesen, E. Hommel, and H.P. Hansen Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria BMJ 319 1999 24 25
16. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group Lancet 349 1997 1787 1792
17. J. Kvetny, G. Gregersen, and R.S. Pedersen Randomized placebo-controlled trial of perindopril in normotensive, normoalbuminuric patients with type 1 diabetes mellitus QJM 94 2001 89 94
18. M. Ravid, H. Savin, and I. Jutrin Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients Ann Intern Med 118 1993 577 581
19. H.E. Lebovitz, T.B. Wiegmann, and A. Cnaan Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria Kidney Int Suppl 45 1994 S150 S155
20. G.L. Bakris, J.B. Copley, and N. Vicknair Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy Kidney Int 50 1996 1641 1650
21. J. Ahmad, M.A. Siddiqui, and H. Ahmad Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria Diabetes Care 20 1997 1576 1581
22. F.S. Nielsen, P. Rossing, and M.A. Gall Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy Diabetes 46 1997 1182 1188
23. R. Fogari, A. Zoppi, and L. Corradi Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function J Hum Hypertens 13 1999 47 53
24. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group BMJ 317 1998 713 720
25. R.O. Estacio, B.W. Jeffers, and W.R. Hiatt The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension N Engl J Med 338 1998 645 652
26. P. Ruggenenti, A. Perna, and G. Gherardi Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury Am J Kidney Dis 35 2000 1155 1165
27. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators Lancet 355 2000 253 259
28. T. Sano, T. Kawamura, and H. Matsumae Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients Diabetes Care 17 1994 420 424
29. R. Trevisan, and A. Tiengo Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group Am J Hypertens 8 1995 876 883
30. C.D. Agardh, J. Garcia-Puig, and B. Charbonnel Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine J Hum Hypertens 10 1996 185 192
31. M. Ravid, R. Lang, and R. Rachmani Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study Arch Intern Med 156 1996 286 289
32. M. Ravid, D. Brosh, and Z. Levi Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: a randomized, controlled trial Ann Intern Med 128 1998 982 988
33. G. Maschio, D. Alberti, and G. Janin Effect of the angiotensin- converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group N Engl J Med 334 1996 939 945
34. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Lancet 349 1997 1857 1863
35. P. Ruggenenti, A. Perna, and G. Gherardi Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy Lancet 352 1998 1252 1256
36. P. Ruggenenti, A. Perna, and R. Benini In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia J Am Soc Nephrol 10 1999 997 1006
37. P. Ruggenenti, A. Perna, and G. Gherardi Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria Lancet 354 1999 359 364
38. T.H. Jafar, C.H. Schmid, and M. Landa Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data Ann Intern Med 135 2001 73 87
39. J.T. Wright Jr., G. Bakris, and T. Greene Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial JAMA 288 2002 2421 2431
40. E.J. Lewis, L.G. Hunsicker, and W.R. Clarke Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
41. B.M. Brenner, M.E. Cooper, and D. de Zeeuw Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
42. H.H. Parving, H. Lehnert, and J. Brochner-Mortensen The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 2001 870 878
43. G. Viberti, and N.M. Wheeldon Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect Circulation 106 2002 672 678
44. C.E. Mogensen, S. Neldam, and I. Tikkanen Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study BMJ 321 2000 1440 1444
45. P. Jacobsen, S. Andersen, and K. Rossing Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy Kidney Int 63 2003 1874 1880
46. P. Jacobsen, S. Andersen, and B.R. Jensen Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy J Am Soc Nephrol 14 2003 992 999
47. R. Campbell, F. Sangalli, and E. Perticucci Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies Kidney Int 63 2003 1094 1103
48. J. Segura, M. Praga, and C. Campo Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses J Renin Angiotensin Aldosterone Syst 4 2003 43 47
49. N. Nakao, A. Yoshimura, and H. Morita Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial Lancet 361 2003 117 124
50. L.M. Ruilope, J.C. Aldigier, and C. Ponticelli Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease J Hypertens 18 2000 89 95
51. G.L. Bakris, and M.R. Weir Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 160 2000 685 693
52. G.L. Bakris, M. Siomos, and D. Richardson ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group Kidney Int 58 2000 2084 2092
53. S.R. Orth, M. Schomig, and E. Ritz Pharmacological intervention in progressive renal diseases Nephrol Dial Transplant 16 Suppl 5 2001 19 25
54. C.E. Mogensen Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment Scand J Clin Lab Invest 36 1976 383 388
55. H.H. Parving, A.R. Andersen, and U.M. Smidt Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy Lancet 1 1983 1175 1179
56. J. Bergstrom, A. Alvestrand, and H. Bucht Progression of chronic renal failure in man is retarded with more frequent clinical follow-ups and better blood pressure control Clin Nephrol 25 1986 1 6
57. P. Kes, and I. Ratkovic-Gusic The role of arterial hypertension in progression of renal failure Kidney Int Suppl 55 1996 S72 S74
58. M.J. Klag, P.K. Whelton, and B.L. Randall Blood pressure and end-stage renal disease in men N Engl J Med 334 1996 13 18
59. S. Klahr, A.S. Levey, and G.J. Beck The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group N Engl J Med 330 1994 877 884
60. J.C. Peterson, S. Adler, and J.M. Burkart Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study Ann Intern Med 123 1995 754 762
61. A.V. Chobanian, G.L. Bakris, and H.R. Black Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Hypertension 42 2003 1206 1252
62. P. Ruggenenti, A. Perna, and R. Benini Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN) J Am Soc Nephrol 9 1998 2096 2101
63. L.Y. Agodoa, L. Appel, and G.L. Bakris Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial JAMA 285 2001 2719 2728
64. J. Oliver, M. MacDowell, and Y.C. Lee Cellular mechanisms of protein metabolism in the nephron I. The structural aspects of proteinuria, tubular absorption, droplet formation, and the disposal of proteins J Exp Med 99 1954 589 604
65. G. Remuzzi, and T. Bertani Pathophysiology of progressive nephropathies N Engl J Med 339 1998 1448 1456
66. P. Ruggenenti, A. Perna, and G. Remuzzi Retarding progression of chronic renal disease: the neglected issue of residual proteinuria Kidney Int 63 2003 2254 2261
67. P. Rossing, E. Hommel, and U.M. Smidt Reduction in albuminuria predicts diminished progression in diabetic nephropathy Kidney Int Suppl 45 1994 S145 S149
68. A.J. Apperloo, D. de Zeeuw, and P.E. de Jong Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease Kidney Int Suppl 45 1994 S174 S178
69. P. Rossing, E. Hommel, and U.M. Smidt Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment Diabetologia 37 1994 511 516
70. D. de Zeeuw, G. Remuzzi, and H.H. Parving Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL Kidney Int 65 2004 2309 2320
71. T.H. Jafar, P.C. Stark, and C.H. Schmid Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease Kidney Int 60 2001 1131 1140
72. W.F. Keane, B.M. Brenner, and D. de Zeeuw The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study Kidney Int 63 2003 1499 1507
73. S. Yusuf, P. Sleight, and J. Pogue Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 2000 145 153
74. D. de Zeeuw, G. Remuzzi, and H.H. Parving Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy Circulation 110 2004 921 927
75. T. Addis Glomerular nephritis: diagnosis and treatment 1947 Macmillan New York
76. T.H. Hostetter, J.L. Olson, and H.G. Rennke Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation Am J Physiol 241 1981 F85 F93
77. A.S. Levey, T. Greene, and G.J. Beck Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group J Am Soc Nephrol 10 1999 2426 2439
78. M.T. Pedrini, A.S. Levey, and J. Lau The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis Ann Intern Med 124 1996 627 632
79. B.L. Kasiske, J.D. Lakatua, and J.Z. Ma A meta-analysis of the effects of dietary protein restriction on the rate of decline in renal function Am J Kidney Dis 31 1998 954 961
80. W.E. Mitch Dietary therapy in uremia: the impact on nutrition and progressive renal failure Kidney Int Suppl 75 2000 S38 S43
81. M.W. Taal, and B.M. Brenner Prevention of progressive renal failure H.R. Brady C.S. Wilcox Therapy in nephrology and hypertension, companion to Brenner and Rector's the kidney 2003 WB Saunders Philadelphia 641 653
82. M. Ravid, D. Brosh, and D. Ravid-Safran Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia Arch Intern Med 158 1998 998 1004
83. L.G. Hunsicker, S. Adler, and A. Caggiula Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study Kidney Int 51 1997 1908 1919
84. M. Manttari, E. Tiula, and T. Alikoski Effects of hypertension and dyslipidemia on the decline in renal function Hypertension 26 1995 670 675
85. P. Muntner, J. Coresh, and J.C. Smith Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study Kidney Int 58 2000 293 301
86. H.T. Yu Progression of chronic renal failure Arch Intern Med 163 2003 1417 1429
87. L.F. Fried, T.J. Orchard, and B.L. Kasiske Effect of lipid reduction on the progression of renal disease: a meta-analysis Kidney Int 59 2001 260 269
88. S. Bianchi, R. Bigazzi, and A. Caiazza A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease Am J Kidney Dis 41 2003 565 570
89. H.C. Gerstein, J.F. Mann, and J. Pogue Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators Diabetes Care 23 Suppl 2 2000 B35 B39
90. H.P. Chase, S.K. Garg, and G. Marshall Cigarette smoking increases the risk of albuminuria among subjects with type I diabetes JAMA 265 1991 614 617
91. P.T. Sawicki, U. Didjurgeit, and I. Muhlhauser Smoking is associated with progression of diabetic nephropathy Diabetes Care 17 1994 126 131
92. T. Chuahirun, and D.E. Wesson Cigarette smoking predicts faster progression of type 2 established diabetic nephropathy despite ACE inhibition Am J Kidney Dis 39 2002 376 382
93. I. Muhlhauser, H. Overmann, and R. Bender Predictors of mortality and end-stage diabetic complications in patients with type 1 diabetes mellitus on intensified insulin therapy Diabet Med 17 2000 727 734
94. S.R. Orth Smoking and the kidney J Am Soc Nephrol 13 2002 1663 1672
95. S.R. Orth, A. Stockmann, and C. Conradt Smoking as a risk factor for end-stage renal failure in men with primary renal disease Kidney Int 54 1998 926 931
96. A. Mimran, J. Ribstein, and G. DuCailar Albuminuria in normals and essential hypertension J Diabetes Complications 8 1994 150 156
97. M. Regalado, S. Yang, and D.E. Wesson Cigarette smoking is associated with augmented progression of renal insufficiency in severe essential hypertension Am J Kidney Dis 35 2000 687 694
98. H.M. Perry Jr., J.P. Miller, and J.R. Fornoff Early predictors of 15-year end-stage renal disease in hypertensive patients Hypertension 25 1995 587 594
99. M.M. Ward, and S. Studenski Clinical prognostic factors in lupus nephritis: the importance of hypertension and smoking Arch Intern Med 152 1992 2082 2088
100. S.J. Pinto-Sietsma, J. Mulder, and W.M. Janssen Smoking is related to albuminuria and abnormal renal function in nondiabetic persons Ann Intern Med 133 2000 585 591
101. H. Schiffl, S.M. Lang, and R. Fischer Stopping smoking slows accelerated progression of renal failure in primary renal disease J Nephrol 15 2002 270 274
102. J. Rossert, B. Fouqueray, and J.J. Boffa Anemia management and the delay of chronic renal failure progression J Am Soc Nephrol 14 2003 S173 S177
103. D. Roth, R.D. Smith, and G. Schulman Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients Am J Kidney Dis 24 1994 777 784
104. S. Kuriyama, H. Tomonari, and H. Yoshida Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients Nephron 77 1997 176 185
105. P. Jungers, G. Choukroun, and Z. Oualim Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients Nephrol Dial Transplant 16 2001 307 312
106. B.G. Delano Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients Am J Kidney Dis 14 1989 14 18
107. R.W. Evans, B. Rader, and D.L. Manninen The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group JAMA 263 1990 825 830
108. K.S. Kleinman, S.U. Schweitzer, and S.T. Perdue The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial Am J Kidney Dis 14 1989 486 495
109. D.S. Silverberg, D. Wexler, and A. Iaina The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron? J Nephrol 17 2004 749 761
110. Morbidity and mortality of renal dialysis: an NIH consensus conference statement. Consensus Development Conference Panel Ann Intern Med 121 1994 62 70
111. J.E. Hall, M.W. Brands, and J.R. Henegar Abnormal kidney function as a cause and a consequence of obesity hypertension Clin Exp Pharmacol Physiol 25 1998 58 64
112. A. Chagnac, T. Weinstein, and A. Korzets Glomerular hemodynamics in severe obesity Am J Physiol Renal Physiol 278 2000 F817 F822
113. M. Praga, E. Hernandez, and A. Andres Effects of body-weight loss and captopril treatment on proteinuria associated with obesity Nephron 70 1995 35 41
114. M. Praga Obesity: a neglected culprit in renal disease Nephrol Dial Transplant 17 2002 1157 1159
115. M. Praga, E. Hernandez, and J.C. Herrero Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy Kidney Int 58 2000 2111 2118
116. E. Morales, M.A. Valero, and M. Leon Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies Am J Kidney Dis 41 2003 319 327